Rosiglitazone metformin adduct inhibits hepatocellular carcinoma proliferation via activation of AMPK/p21 pathway

Title
Rosiglitazone metformin adduct inhibits hepatocellular carcinoma proliferation via activation of AMPK/p21 pathway
Authors
Keywords
Rosiglitazone metformin adduct, Hepatocellular carcinoma, Proliferation, Metformin, AMPK/p21 pathway
Journal
Cancer Cell International
Volume 19, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-01-11
DOI
10.1186/s12935-019-0732-2

Ask authors/readers for more resources

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now